Could a weekly injection free people with type 1 diabetes from carb counting?

NCT ID NCT07284511

Recruiting now Disease control Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether tirzepatide, a weekly injection already used for type 2 diabetes, can help adults with type 1 diabetes use an automated insulin pump without needing to count carbohydrates at meals. About 105 participants will be randomly assigned to receive tirzepatide or continue standard care. The goal is to see if tirzepatide can safely maintain good blood sugar control while reducing the daily burden of diabetes management.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for T1D are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Overweight type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

T1D T1DM T1DM - TYPE 1 DIABETES MELLITUS TYPE 1 DIABETES TYPE 1 DIABETES MELLITUS

Contacts and locations

Locations

Hygea Medical Clinic
RECRUITING

Montreal, Quebec, H4A 3T2, Canada
Insel Hospital, University Hospital Bern
NOT_YET_RECRUITING

Bern, 3010, Switzerland
Institut de Recherches Cliniques de Montréal
NOT_YET_RECRUITING

Montreal, Quebec, H2W 1R7, Canada
McGill University Health Centre
NOT_YET_RECRUITING

Montreal, Quebec, H4A 3J1, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.